Battiwalla Minoo, Fakhrejahani Farhad, Jain Natasha A, Klotz Jeffrey K, Pophali Priyanka A, Draper Debbie, Haggerty Janice, McIver Zachariah, Jelinek James, Chawla Kamna, Ito Sawa, Barrett John
Hematology. 2014 Jul;19(5):275-9. doi: 10.1179/1607845413Y.0000000131. Epub 2013 Nov 25.
Frequent diagnostic radiology procedures in allogeneic stem cell transplantation (SCT) recipients raise concern about the potential harm from incidental radiation.
To determine the cumulative radiation dose from diagnostic studies in allogeneic SCT and its impact on clinical outcome.
This retrospective cohort study was conducted to determine the cumulative radiation dose from diagnostic studies following SCT. Sixty-four consecutive patients with hematological malignancies in a single tertiary care institution underwent total body irradiation (TBI)-based myeloablative conditioning followed by six of six human leukocyte antigen (HLA)-identical sibling allogeneic SCT. The median follow-up was 3 years. The cumulative effective dose in mSv from diagnostic radiological studies in the peri-transplant period from day -30 to day +200 was calculated for each patient and its impact on overall survival and non-relapse mortality was determined.
The median cumulative radiation exposure from diagnostic radiological procedures was 92 mSv (range 1.2-300), representing about 30× the normal annual background radiation for the population and 10% of the 1200 cGy TBI dose used in conditioning. Sixty-five percent of the cumulative radiation exposure was delivered between day +1 and day 100 and computed tomography scans contributed 88%. In multivariate analysis, diagnostic procedures did not significantly impact clinical outcomes.
While radiation exposure from diagnostic procedures did not impact clinical outcomes the risk of secondary cancers in long-term survivors is likely to be increased. Our results indicate that patients who are acutely ill for prolonged periods can receive clinically significant radiation doses during their hospital care. Our findings should prompt attempts to limit radiation exposure from diagnostic procedures in post-SCT recipients.
异基因造血干细胞移植(SCT)受者频繁进行诊断性放射学检查引发了对偶然辐射潜在危害的担忧。
确定异基因SCT中诊断性检查的累积辐射剂量及其对临床结局的影响。
本回顾性队列研究旨在确定SCT后诊断性检查的累积辐射剂量。在一家三级医疗机构中,64例连续的血液系统恶性肿瘤患者接受了基于全身照射(TBI)的清髓预处理,随后接受了6/6人类白细胞抗原(HLA)相合的同胞异基因SCT。中位随访时间为3年。计算每位患者在移植前后第-30天至第+200天期间诊断性放射学检查的累积有效剂量(单位为毫希沃特),并确定其对总生存和非复发死亡率的影响。
诊断性放射学检查的中位累积辐射暴露量为92毫希沃特(范围为1.2 - 300),约为人群正常年度本底辐射的30倍,是预处理中使用的1200厘戈瑞TBI剂量的10%。65%的累积辐射暴露发生在第+1天至第100天之间,计算机断层扫描贡献了88%。在多变量分析中,诊断性检查对临床结局无显著影响。
虽然诊断性检查的辐射暴露未影响临床结局,但长期存活者发生继发性癌症的风险可能增加。我们的结果表明,长期患重病的患者在住院治疗期间可能接受具有临床意义的辐射剂量。我们的发现应促使人们尝试限制SCT后受者诊断性检查的辐射暴露。